Have you been newly diagnosed with breast cancer? Are you struggling to make treatment choices?
Then you may be interested to know that many women with early-stage breast cancer do not benefit from chemotherapy. For some women, chemotherapy may not add any significant medical advantage.
The Oncotype DX® test is a diagnostic test that helps identify which women with early-stage, estrogen-receptor-positive and lymph-node-negative breast cancer are more likely to benefit from adding chemotherapy to their hormonal treatment. This test also helps assess the likelihood that an individual woman’s breast cancer will return. The Oncotype DX test provides important information that you and your doctor may use when making decisions about treatment. Post-menopausal women recently diagnosed with node-positive, hormone-receptor-positive breast cancer may also be appropriate candidates for the Oncotype DX test.